Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
VISEN Pharmaceuticals ( (HK:2561) ) has provided an announcement.
VISEN Pharmaceuticals has entered into a Commercial Supply Framework Agreement with Ascendis Europe to purchase drug packages, auto-injectors, and ancillary products. This agreement aims to meet the strong market demand for VISEN’s lonapegsomatropin products following its Global Offering. The transactions under this agreement are subject to specific reporting and approval requirements due to the connected nature of the parties involved, reflecting the company’s strategic efforts to secure its supply chain and enhance its market positioning.
More about VISEN Pharmaceuticals
VISEN Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and distribution of therapeutic products. Its primary products include lonapegsomatropin, which is used for addressing growth hormone deficiencies. The company is committed to meeting market demands and ensuring continuous access to its drugs for patients and healthcare providers.
Average Trading Volume: 175,119
Learn more about 2561 stock on TipRanks’ Stock Analysis page.